BSI-301: Preclinical Iodothyronine Program
BSI-301 is our lead compound in our iodothyronine program in preclinical development with anti-tubulin properties. Iodothryonine targets cancer cells by relying on the role thyroid hormones play in cell proliferation, cell death and angiogenesis.
Learn more about the candidates in our PARP Inhibitor Program:
- BSI-201: Lead Product and Clinical Stage PARP Inhibitor (IV)
- BSI-401: Follow-on PARP Inhibitor (Oral)